LAMIVUDINE 150 mg Tablets (Box of 60)

Nucleoside Reverse Transcriptase Inhibitor (NRTI) – Antiretroviral and Anti-Hepatitis B Agent

ATC Code: J05AF05 | Prescription Only | WHO Essential Medicine

---

Product Description:

Lamivudine is a synthetic cytidine analog and a widely used nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV-1 infection and chronic hepatitis B (HBV). It inhibits viral replication by incorporating into viral DNA and causing chain termination. It is one of the most extensively studied and prescribed antiretrovirals and is a core component of many WHO-recommended ART regimens.

The 150 mg strength is used in twice-daily antiretroviral therapy (ART) or in weight-band pediatric dosing, and is often co-administered with zidovudine, abacavir, or tenofovir disoproxil fumarate.

Available Presentation:

• Strength: 150 mg per tablet
• Formulation: Film-coated or uncoated tablet (color varies by manufacturer)
• Packaging: Bottle of 60 tablets (supply for twice-daily dosing)
• Route of Administration: Oral
• Storage Conditions: Store below 30°C; keep in a dry place; protect from light

Uses:

• As part of combination antiretroviral therapy (cART) for HIV-1 infection in adults, adolescents, and children
• Treatment of chronic hepatitis B infection, particularly in co-infected patients or where other options are not tolerated
• Included in WHO and PEPFAR regimens for:
  • First-line and second-line HIV therapy
  • Pediatric ART protocols
  • Prevention of mother-to-child transmission (PMTCT) programs

Indications:

• HIV-1 infection:
  • In combination with at least one other antiretroviral for treatment of HIV-1
  • For adults, adolescents, and pediatric patients weighing ≥14 kg
• Chronic Hepatitis B infection:
  • For HBV monoinfection or HIV/HBV co-infected individuals when preferred agents are unavailable
  • Often used in immunocompromised patients or children

Regulatory and Safety Profile:

• ATC Code: J05AF05
• Pharmacologic Class: Nucleoside Reverse Transcriptase Inhibitor (NRTI)
• Pregnancy Category: B – Safe in all trimesters of pregnancy
• Common Adverse Effects: Headache, fatigue, nausea, cough, abdominal discomfort
• Serious Risks: Lactic acidosis, hepatomegaly with steatosis, pancreatitis (rare in adults, more common in children), HBV flare after discontinuation
• Contraindications: Known hypersensitivity to lamivudine or excipients
• Monitoring Parameters: Liver enzymes (especially in HBV), renal function, HIV viral load, HBV DNA levels if co-infected

---

For pricing, institutional availability, and supply to HIV or HBV treatment programs, contact us at info@panamfarma.com.